AcrAB-ToIC is the major efflux protein complex in Escherichia coli extruding a vast variety of antimicrobial agents from the cell. The inner membrane component AcrB is a homotrimer, and it has been postulated that the monomers cycle consecutively through three conformational stages designated loose (l). tight (T), and open (0) in a concerted fashion. Binding of drugs has been shown at a periplasmic deep binding pocket in the T conformation. The initial drug-binding step and transport toward this drug-binding site has been elusive thus far. Here we report high resolution structures (1.9-2.25 A) of AcrB/designed ankyrin repeat protein (DARPin) complexes with bound minocycline or doxorubicin. In the AcrB/doxorubicin cocrystal structure. binding of three doxorubicin molecules is apparent; with one doxorubicin molecule bound in t he deep binding pocket of the T monomer and two doxorubicin molecules in a stacked sandwich arrangement in an access pocket at the lateral periplasmic cleft of the l monomer. This access pocket is separated from the deep binding pocket apparent in the T monomer by a switch-loop. The localization and conformational flexibility of this loop seems to be important for large substrates. because a G616N AcrB variant deficient in macrolide transport exhibits an altered conformation within this loop region. Transport seems to be a stepwise process of initial drug uptake in the access pocket of the l monomer and subsequent accommodation of the drug in the deep binding pocket during the L to T transition to the internal deep binding pocket of the T monomer.
antibiotics I multidrug resista nce I drug ef fl ux I RND transporter T he three-component AcrA/AcrBrrolC multidrug resistance pump provides the Gram-negative Escherichia coli cell wit~ the necessa ry means to protect itself against a wide range of noxious compounds (1) . AcrB resides in the inner membrane and is the energy transducing and substrate specificity determinant of the entire three-component pump asse mbly (2, 3) . AcrA is the adapter component that associates the inner membrane pump with the TolC outer membrane channel (4, 5) . Importantly, all three components are necessary to obtain the multidrug resistance phenotype (3, 4) .
T he first de novo AcrB crysta l structure was solved via X-ray clystallography at 3.5 A resolu tion by Murakami et a!. (6) in 2002 [Protein Data Bank (PDB) ID code lIWG] and showed a ligand-free homotrimeric assembly ( Fig. Sl A and B) . Each monomer contains a 12 transm embrane helices (TMs)-containing transmembrane domain, with TM4 and TMI0 harboring essential titratable resid ues (D407, D408, and K940) inside the topological core (7) (Fig. SIC) .
Approximately half of the protein 's 1,049 amino acids form two extensive peri plasmic loops connecting TMI with TM2 and TM7 wit h TM8 and extends 70 A into th e periplasm, comprising the TolC docking domain and a porter domai n ( Fig. Sl A and B) .
T he latter domain is divided in subdo mains PNI , PN2, PCI, and PC2, which are coupled by seq uential proximity (PNI-PN2, PCl-PC2) and by sharing ~-strands to form common ~-sheets (PN2-PCI, PC2-PNI) (Fig. SID) . Between the PCI and PC2 subdomains a cleft is apparent, oriented approximately perpendicul ar to the membrane plane ( Fig. Sl B and D) . In the center of the trimer, the TolC docking domain exhibits a funnel-li ke structure narrowing to a central pore, defined by a-helices (designated pore helices) of the PNI subdomains of each monomer. T his pore has a small diameter and does not allow drugs to pass. Toward the membrane plane, the central pore leads to a central cavity and further to a 30-to 35-A-wide, presumably lipid-filled transmembrane hole defined by the ring-like arrangement of the TMs of the trimer (Fig. Sl) . Three vestibules at the monomer ' interface located just above the membrane plane lead toward the central cavity ( Fig. SI A and B) . The periplasmic boundaries of these vestibule areas were recently shown to be accessible for the AcrB substrate Bodipy FL N-(2-aminoet hyl) male imide (8) . Moreover, the substrate specificity of the entire AcrAB-TolC effl ux machinery was found to be localized in the AcrB periplasmic porter domain (2) , whereas the AcrB transmembrane domain seems to be essential for proton translocation (7, 9) (Fig. SI) .
In 2006, three groups independently published an asymmetric structure of AcrB grown in the monoclinic space group C2 (10-12) (PDB entries: 2DHH, 2DR6, 2DRD, and 2GIF, 2.8-2.9 A), triclinic space gro up PI (11) (2HRT, 3.0 A), and an AcrB structure including bound designed ankyrin repeat proteins (DARPins) grown in orthorhombic space gro up P212121 (2J8S, 2.5 A) (12) . Within the asymmetric AcrB trimer, each monomer has a different conformation denoted as loose (L), tight (T), and open (0) (access, binding, and extrusion, respectively) (10) (11) (12) , with the L (or access) state closest to the conformati on of the monomers in the symmetric structure (6) . Two of the deposited asymmetric structures based on 3.1-an d 3.3-A data of AcrB/ minocycline and AcrB/doxorubicin co crystals, respectively (10), showed binding of (9-bromo) minocycline or doxorubicin to a hydrophobic binding pocket exclusively present in one of the monomers (the T or binding monomer) within the asymmetric AcrB trimer. The DARPin bound AcrB structure was almost identical to the AcrB structures crystallized without binder, with rmsd of the superimposed trim eric structures ~1 A. The DARPin molecules only bind to the Land T conformers, resulting in a ratio of two DARPin molecules per AcrB trimer. This stoichiometry was verified by densitometry after microchannel electrophoresis, sedimentation velocity experiments, and via laser-induced liquid bead ion desorption mass spectrometry, suggesting that in solution and probably also in vivo AcrB adopts mainly the asymmetric conformation (12, 13) .
In analogy with the functional rotation of the alP-subunits of the FIFo ATPase leading to synthesis of ATP (14), a similar catalytic mechanism was postulated for AcrB leading to drug export (10) (11) (12) . In short, the hypothesis states that within the asymmetric trimer, the monomers can adopt any of the conformational states L, T, and O. Transport depends on the concerted-but not necessarily synchronous-cycling of the monomers through the states L, T, 0, and back to L, which is the essence of the functional rotation. In the L conformation, substrates are recruited from the peri plasmic space and/or the membrane for transport during the L to T transition toward the deep substrate binding pocket inside the porter domain. Upon conformational change toward the 0 state, substrate is released from the binding pocket and exits AcrB via its central funnel toward the TolC tunnel. During a complete functional rotation, occlusions and constrictions inside the porter domain seem to propagate from a lateral opening toward the central funnel driving the unidirectional transport of substrate. Hence, this mechanism was dubbed "peristaltic pump mechanism" (11, 15, 16) (Fig. Sl E-G) . The conversion from T to 0 is suggested to be the energy-requiring step, in analogy to the binding change mechanism for the FIFo ATPase (14) . Drug efflux is also subject of bi-site activation; that is, the T to 0 transition within the LTO trimer (and the resulting release of the drug) only occurs when additional substrate has bound to the adjacent monomer. Strengthening this view are the recently observed strong cooperative kinetics of the extrusion of p-lactam antibiotics by the AcrAB-ToIC system (17, IS).
The functional rotation mechanism suggests interdependence of the monomers, which means that inactivation of only one of the monomers will render the entire trimer inactive. Recently, this has been impressively shown to be the case by Nikaido and coworkers by the use of a covalently linked AcrB trimer (19) . The proposed conformational cycling and the substantial rearrangement of the periplasmic subdomains was analyzed in vivo by the introduction of cysteine pairs (20, 21) , whereby formation of disulfide bonds significantly decreased AcrB-mediated transport and restoring activity by the addition of the reducing reagent DTT.
Two conformationally distinct trimeric AcrB structures are known to date: the symmetric LLL (all loose) conformation (6) and the asymmetric LTO conformation (10) (11) (12) . The very recently published crystal structure of the Cu+ and Ag+ transporter CusA from E. coli showed substrates bound to the periplasmic porter domain in all three protomers adapting a symmetric conformation with structural features describing a TTT conformation (22) .
Most of the published AcrB· structures are in the symmetric conformation but show in particular cases slight deviations between each other, indicating intrinsic flexibility (6, 7, (23) (24) (25) (26) . The LLL conformation has been postulated the "resting state"-in the absence of substrate (7, 15) -with the structural flexibility necessaty for substrate acquisition (25) . Recently published symmetric LLL state structures (at 3.S5-to 3.2-A resolution) were shown to accommodate substrates to the inner wall of the transmembrane cavity (25) (26) (27) or in the open cleft determined by 5688 the PC1/PC2 subdomains, constituting the access to tunnel 2 (Fig. Sl E and F) (24, 27) . One transport hypothesis assumes the substrate to be garnered from the outer leaflet of the inner membrane or directly from the periplasm. Substrates that are partitioned in the outer leaflet of the inner membrane might enter the L monomer via the TMS/TM9 groove, whereas substrates located in the periplasm might enter the L monomer via the PCl/PC2 cleft (i.e., the entrance of tunnel 2 ~15 A above the membrane plane) (Fig. SlE ) . Additionally, a concerted and consecutive drug uptake via the TMS/TM9 groove and subsequent transport to the PCl/PC2 cleft might be envisioned.
High-resolution (2.5 A) data describing the asymmetric trimer show clear densities in the TMS/TM9 groove of the L monomer, which has been attributed to the highly concentrated detergent and AcrB substrate n-dodecyl-p-D-maltoside (12) . Upon conformational change from the L to the T state, tunnel 1 appears and might provide one of the pathways for substrates toward the hydrophobic deep binding pocket that accommodates the substrate molecule.
Upon transition from the T to the 0 state, the binding pocket closes again; substrate is squeezed out and follows a newly formed tunnel (tunnel 3) to the funnel, and is from there finally extruded into the medium via TolC (Fig. Sl) .
In the work presented here, high-resolution structures (1.9 and 2.25 A) describe a potential initial binding step of doxorubicin in the L conformer, and multiple substrate (minocycline or doxorubicin and dodecyl-a-D-maltoside) binding to the T conformer. Access to the internal deep binding pocket in the T monomer is mediated by the conformational change from the L to the T conformation. In the L monomer, two doxorubicin molecules are positioned in an access pocket and separated from the internal binding pocket by a flexible loop, designated switch-loop, containing F615 and F617. The observations lead to the hypothesis of a stepwise transport of drugs initially bound to the access pocket in the L conformation and subsequent transport to the deep binding pocket by the conformational change of the switchloop and the PN2/PCl subdomains during the L to T transition.
Results

Binding of Minocycline and Doxorubicin by the AcrB Wild-Type
Protein. We describe here the ctystallization and structural elucidation of AcrB/DARPin complexes in the presence of minocycline and doxorubicin based on 1.9-A and 2.25-A diffraction data (Table Sl) . AcrB/DARPin complexes were Coctystallized in the presence of minocycline (2.0 mM) or doxorubicin (0.4 mM), yielding orthorhombic crystals. The structures were refined to an R frcc of 23.1 % and 22.7%, respectively, and describe an asymmetric trimer comprising three different monomer conformations representing the consecutive states L, T, and 0 (15). Electron densities for minocycline or doxorubicin could be clearly identified ' in the hydrophobic deep binding pocket of the T monomer ( Fig. 1 and Fig. S2 ). Whereas the position of minocycline is congruent with the structure of Murakami et al. (10) , the orientation of the doxorubicin molecule inside the deep binding pocket differs substantially (Fig. S2 and Table S2 ). Notably, differences in ctystallization conditions and resolution, and our use of crystallization chaperones (DARPins), are possible reasons for the observed distinctions. In the T monomer, another density located in the lateral cleft determined by the PC1 and PC2 subdomains of the peri plasmic porter domain could be assigned to dodecyl-a-D-maltoside (Fig. S3 ). In the L monomer of the AcrB/doxorubicin cocrystal structure, but not in the AcrB/ minocycline Coctystal structure, large densities were observed at the PCl/PC2 subdomain cleft (access pocket) and could be assigned to a twofold symmetric sandwich of stacked doxorubicin molecules ( Fig. 2 and Fig. S4 ). The AcrB/doxorubicin cocrystal structure therefore reveals an asymmetric AcrB trimer containing three doxorubicin molecules: two doxorubicin molecules Coordi nation of doxorubicin by residues inside the AcrB access pocket includes hydrophobic interactions with F666 and L828 and charged/polar interactions with T676, R717, and N719 (Fig. S4) . In a recent study, these coordination sites and further proximate residues (D566, F664, L668, and E673; Fig. S4 ) were Cys-s ubstituted and accessible to the AcrB substrate Bodipy FL maleimide (28) , matching the clystallographic data presented here (Fig. S4B ) . Furthermore, single alanine substitution of residues F664, F666, E673, and R717 markedly interfered with the ability of these AcrB variants to confer resistance toward various toxic compounds (27) .
The L monomer is considered the access protomer (10, 11) involved in th e initial stage of drug binding. The lateral access pocket at the periplasmic cleft confined by the PC1 and PC2 subdomains might be the initial entry point for drugs to the AcrB funct ional rotation cycle. However, many of the AcrB substrates are expected also to partition into the outer leaflet of the inner membrane because of th eir hydrophobic properties. A suggested entIy pathway for drugs partitioned in the outer leaflet of the inner membrane is the hydrophobic groove in the transmembrane domain defined by TM8 and TM9 (6, 15) , where in the high-resolution structures presented here, binding of the detergent and AcrB substrate dodecyl-~-D-maltoside is apparent (Fig. S6 A and B) .
T he TM8/TM9 groove defin es the entrance to tunnel 1 ( Fig.  SlF) (12, 15) inside the peri plasmic porter domain, which leads toward the hydrophobic deep binding pocket (10) (11) (12) . This tunnel and the opening of the deep binding pocket with subseq uent minocycline or doxorubicin binding are appa re nt after the L to T transition ( Fig. 1 and ref. 10) . T he L monomer of the AcrB/doxorubicin structure comprises one dodecyl-p-D-maltoside molecule at the TM8/TM9 transmembrane groove and a doxorubicin dimer sandwich at the access pocket (Figs. S4 and  S6 ). The access pocket and the TM8/TM9 groove might represent exclusive e ntIy points for drugs with different properties, or consecutive gates in a multistep transport mechanism.
A Switch-Loop Separates Access and Deep Binding Pocket Areas. The doxorubicin molecules in th e access pocket of the L monomer are separated from the deep binding pocket (Fig. 1) by a loop containing F615, F617, and R620 (switch-loop; Fig. 2A and B) .
The switch-loop adopts alternative conformations in the Land T monomer. It seems to modulate the path from the access pocket in the L conformation to the deep binding pocket in the T conformation. Superimposition of the Land T conformations indicates that the side chain conformation of F615 (located on th e switch-loop) and Q176 (located on the PN2 subdomain) seen in the L monomer would interfere with doxorubicin binding in the deep binding pocket, and the switch-loop main chain conformation in the T conformation would sterically interfere with the stacked doxorubicin location as observed in the L conformation. Therefore, steric hindrance presumably precludes binding of the drugs in the deep binding pocket in the L monomer, wh ereas the alternative loop conformation seems to prevent binding of doxorubicin to th e access pocket in the T conformation (Fig. 2B ) . The switch-loop conformation in the structure of the symmetric AcrB (i.e., the LLL conformation) is less inward oriented and would theoretically interfere with doxorubicin binding if these would loca lize at the same position as obselved in the asymmetric LTO AcrB trimer (Fig. S7) . Substrates like ethidium (PDB ID code: 1T9X, 3.1 A) (27) or taurocholate (PDB ID code: 2W1B, 3.85 A) (24) seem to bind more at the periphelY of the PC1/PC2 cleft compared with doxorubicin binding in the asymmetric coclystal structure (Fig. S7C) .
It was recently reported (29) that a single substitution in the switch loop (G616N) decreases AcrB's ability to extrude macrolides, resembling the poor effl ux activity toward macrolides shown by the Pseudomonas aeruginosa homolog MexB (wild-type MexB co ntains N616). The switch-loop conformation in the L conformation of the AcrB G616N variant (solved at 2.9 A in the presence of minocycline; Table Sl) resembles the loop conformation of wild-type AcrB in the T monomer and of the switchloop conformation found in the wild-type MexB L monomer structure ( Fig. 2 B and C) . T he differences in the switch-loop conformatio ns between the wild-type AcrB a nd G616N variant are clearly defined by the differences in electron density in this region of the protein (Fig. S6 C and D) .
Superimposition of the L monomer structure of MexB or AcrB G616N variant on the AcrB wild-type L monomer structure predicts a minor steric clash with one of the doxorubicin molecules bound the access pocket of wild-type AcrB (Fig. 2C) . We conducted a drug resistance assay on solid medium usi ng E. coli BW25113tlacrB comprising wild-type or G616N AcrB equ ally well expressed from plasm ids (Fig. S8) of the G616N subst itution on th e resistance against erythromycin could be detected, and a subtle diffe re nce in growth in the presence of doxorubicin was observed . Growth on other substI'ates like novobiocin, ethidium, or chloramphenicol was, however, also slightly affected by th e substitution in various degrees. In minimal inhibitory concentration (MIC) experim e nts re ported recently (29) using liquid medi a and chromosomal substitutio n of the G616N variant in an E. coli AGlOO background, larger macrolide molecules were substantially less well transported by this variant, whereas other substrates li ke novobiocin, ethidium, and chloramphe nicol showed wild-type resistance. Specific sensitivity toward macrolides was also conferred when F615 (localized on the switch-loop) was substituted with Ala, or when residues 615-617 were deleted from the loop (30 The LTO conformation most likely represents the lowest energy form of the AcrB trimer in the presence of substrate (15, 16, 31) , give n that in vivo cross-link studies (21) and analytical ultrace ntrifugation experime nts in the prese nce of DARPins (12, 13) imply th e presence of this conformation in the membrane a nd in detergent rather th an th e readily crystall izable LLL form. The latter state might preferably exist in the absence of ligands (i.e., "resting state"), as has been suggested previously (7, 15, 31) , and apparently is preferred within the R32 crystal lattice. Once substrates a re present in the peri plasmic space and/or partitioned in the periplasmic space/inner-membrane boundary, AcrB-catalyzed efflux of the drugs over the outer membrane is counteracting the influx. The L monomer provides probable initial binding sites for drugs to enter the AcrB protein. One e ntly point might be the TM8/TM9 groove located at the height ofthe peri plasm/membrane boundaly (i.e., the outer lea flet of the inner membrane). In the high-resolution structures presented here (Fig. S6 ) and in the 2.5-A structure by Sennhause r et al. (12) , a dodecyl-p-o-maltoside molecule is deeply buried inside the TM8/TM9 transmembrane groove, unlike the other more loosely bound dodecyl-p-o-maltoside molecul es that were assigned fro m the data of the electron density maps. Moreove r, this groove is located exactly below tunnel 2 (Fig. SlF) in the T monomer leading to the deep binding pocket (12, 15) . In additio n, recent Bodipy FL N-(2-aminoethyl) maleimide labeling data indicated that residue S836, located at the entrance of tunnel 2 o n the PC2 subdomai n, was highly accessible for this AcrB substrate (8) . A second e ntry point is postulated at a late ral access pocket at the periplasmic cleft confined by the PCl and PC2 subdom ai ns (Fig. 2 and Figs. SI Band D, S4, a nd S7 ). Both putative ently sites might represent exclusive access poi nts for drugs with diffe rent properties, or consecutive binding sites. Interestingly, both sites collapse during the proton motive force dependent T to 0 transition sim ultaneo us with the closure of the deep binding pocket and the disappearance of the tunnels leading from both these putative drug entty points toward the deep binding pocket (11, 12, 15) .
The postulated entty step at the periplasmic cleft is depicted by the doxorubicin sandwich inside the access pocket of the L monomer (Fig. 3A) . Binding of substrates (ethidium, rhodamine 60, ciprofloxacin, nafcillin , Phe-Arg-p-naphthylamide, and taurocholate) was also shown in the symmetric L-state trimer (24, 27) at a more lateral position of the PCl/PC2 cleft (Fig. S7) . The more lateral binding might indicate an earlier step in substrate acquisition by the complete ligand-free "resting-state" LLL trimer or might indicate the promiscuity of binding different drugs to different sites within the cleft area . Although it is unclear why two doxorubicin molecules are bound to the L monomer of the asymmetric trimer, it seems that one of the drug molecules can be further transported deeper into the AcrB protein toward the T monomer deep binding pocket (Fig. 38) . VelY recently, coclystal structures from 3.3-A X-ray data showed the binding of high-molecular-mass drugs erythromycin and rifampicin to the access pocket, whereas the low-molecular-mass substrates li ke minocyclin and doxorubicin were postulated to be transported directly to the deep binding pocket, without binding first to the access pocket (32) . Because doxorubicin is mainly present as dimer in solution at concentrations at which the AcrAB-ToIC efflux system confers resistance to E. coli against the drug (and at the concentrations used for cocrystallization) (33) , the binding in a dimeric state in the access pocket might represent a preliminary stage to the binding of the doxorubicin monomer in the deep binding pocket. This entails prerequisite conformation flexibility between the Land T monomer, as well as a binding affinity difference of the access pocket (low affinity) and deep binding pocket (high affinity). The switch-loop and the p-sheets of the PN2/PCl subdomains prohibit entry of the drug in the deep binding pocket in the L conformation (Fig. 2) , and rearrangement of these structures in the L to T transition faci litates access to the deep binding pocket in the T monomer (Fig.  38) . The presence of dodecyl-a-o-maltoside in the PCl/PC2 cleft of the T monomer seems to contradict the predicted function of the switch-loop. The maltoside moiety of dodecyl-a-D-maltoside is localized at the same position as the daunosamine sugar ring of one of the doxorubicin molecules in the L monomer, whereas the aliphatic tail protrudes into the porter domain and seems not to intetiere with the switch loop conformation in the T monomer (Fig. S3) . The presence of dodecyl-a-o-maltoside at this position in the T monomer is puzzling, even more so given that the high resolution of the electron density maps did allow to clearly distinguish between the a-and p-anomers of this detergent. Because only low concentrations of a-anomer are present in the commercial batch of dodecyl-p-o-maltoside, the binding must occur with high affinity for this ligand. Once binding of drug to the deep binding pocket occurs, it is most likely stabilizing the T conformation and is enabling further stabilization by the PNI subdomai n tilting of the neighboring monomer (Fig. 38) . Thus, movement of the subdomains PN2/ PCl in the L to T transition not only takes effect on further conformational changes in the same monomer (Le., T to 0 transition) (Fig. 3C) but is also implied to have an effe~t on the conformational changes in the neighboring monomers.
Movement of the subdomains during the T to 0 transition is coupled to an extensive kinking of TM8, which seems to be coupled to conformational changes in the transmembrane domain. Most likely protonation events [i.e., uptake of protons from the periplasm to the proton relay residues (D407/D408) located in the transmembrane domain] lead to a conformational change of the TMs, and this movement is presumably transduced to TM8, which is connected to the PNl/PC2 subdomains. Once the drug has been released from the 0 conformation, a switch to the L conformation to initiate another round of drug binding in the access pocket seems necessaty (Fig. 3D) . The reorientation of the PNl/PC2 subdomains during the 0 to L transition leads to de-kinking of TM8, which possibly triggers the deprotonation events in the transmembrane domain, stabilizing the L monomer conformation, and a new round of antibiotic uptake via the TM8/ TM9 groove and/or access pocket can be started (Fig. 3) . Molecular insight into coupling of the protonation and deprotonation events in the transmembrane domain to the conformational changes in the periplasmic porter domain leading to drug efflux will eventually provide the complete chain of events of proton motive force-driven drug extrusion by AcrB.
Materials and Methods
Bacterial Strains, Plasmids, and Growth Conditions. E. coli DH51X was used as host for cloning procedures. E. coli C43 (DE3) (34) harboring pET24acrB H1s (35) and pET24acrB His _G616N was used for protein overproduction. LB medium and LB agar (36) were used for routine bacterial growth at 37 'c.
Kanamycin (Applichem) was used at 50 ~g mL -, (Kan so ). Drug resistance was assayed using solid media, as described previously (37) .
Site-Directed Mutagenesis. pET24acrB His (35) served as a template for sitedirected mutagenesis. By using the Quikchange protocol (Stratagene), amino acid substitution was achieved with 5' phosphorylated primers . Insertion of mutation was verified by sequencing (Microsynth) .
Crystallization of AcrB Wild Type and G616N in Presence of DARPins. Overexpression and purification of DARPin clone 1108_19 was accomplished as previously described (12) . AcrB wild-type and AcrB_G616N were overproduced according to the method reported previously (11, 35) , with the following variations for G616N . Expression was induced with IPTG (1 mM) at ODGOO = 0.8, and the culture was incubated overnight at 20 ' c, producing up to 20 mg AcrB_G616N per liter of culture after affinity chromatography. Because of the tendency of AcrB _G616N to aggregate, the protein concentration for crystallization was experimentally determined to be optimal at 8 mg mL -' . DARPins synthesis, purification, and AcrB/DARPin complex crystallization were done accord ing to Sennhauser et al. (12) using ndodecyl -fl-o-maltoside (Glycon; with 0.01 % IX-isomer). Substrate was added before crystallization at cohcentrations of 2 mM and 0.4 mM for minocycline or doxorubicin, respectively. Crystals (Acr8/DARPin and G616N/
